Imatinib (Imkeldi) is the first oral liquid TKI approved for multiple cancers, enhancing treatment accessibility and dosing precision. The drug is effective as a first-line treatment, especially ...

Imkeldi is supplied as a strawberry-flavored oral solution in a 140mL child resistant tamper-evident bottle. The Food and Drug Administration (FDA) has approved Imkeldi, an oral solution ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA has approved IMKELDI (imatinib) oral solution ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing to a wider range of patients, pediatric patients included. The FDA has ...

The FDA has approved imatinib oral solution (Imkeldi) for the treatment of certain forms of leukemia and other cancers. This is the first oral liquid form of imatinib for the treatment of select ...

Updated 96-week data from the ASC4FIRST trial show asciminib significantly outperforms standard TKIs in major molecular ...

On November 25, the Food and Drug Administration (FDA) approved Imkeldi, an oral solution of imatinib, to treat certain types of leukemia and other cancers. In 2001, the FDA approved the original ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377] Draft guidance Technology appraisal guidance 10 January 2025 Cladribine for ...

(Lancet Oncology) Brian Druker, MD, whose discovery of imatinib (Gleevec) paved the way for targeted cancer therapies, announced his resignation as head of the Knight Cancer Institute in Portland ...

Karnataka: Shilpa Medicare has received the Good Manufacturing Practice (GMP) Certification after the successful closure of ...